OCS Stock — Oculis Holding AG

Oculis Holding AG (OCS)

Updated October 16, 2026.

OCS is a Stock. Total return is -24.8% over the past 5.4 years, 124.2 points behind SPY at 99.4%.

Oculis Holding AG is a clinical-stage biopharmaceutical company developing drug candidates for ophthalmic, neuro-ophthalmic, and neurological diseases, with lead programs including OCS-01 for diabetic macular edema in Phase 3 trials, OCS-02 for dry eye disease in Phase 2b trials, and OCS-05 for neuroprotective indications across multiple retinal and optic conditions. As a pre-revenue biotech company, it does not currently distribute to shareholders. This security appeals to investors with risk tolerance for clinical-stage development companies and interest in ophthalmic disease treatment innovation.

OCS performance versus SPY

Price and return data through 2026-10-16.

Total return is -24.8% over the past 5.4 years, 124.2 points behind SPY at 99.4%. Over the past year its total return — price change plus distributions reinvested — is -66.2%. Its deepest 1-year drawdown was 78.0%.

OCS key facts

Asset type

Stock

Asset class

Equity

Inception date

05/18/2021

Distribution frequency

None

Last close

$7.29 (as of 2026-10-16)

Market cap

$448,977,052

Average volume

293677.0

Beta

0.265

Payout ratio

0.0%

EPS

$-1.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OCS risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 78.0%.

Who may consider OCS — and who may not

It is a weaker fit for investors who need monthly cash flow (OCS does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OCS

• All tickers starting with O

Tagged: Healthcare.

Frequently asked questions